Free Submission Public Relations &
Deutsch English


Free Research Reports on CLDX, KWK, SKUL and SQNM Issued by the Bedford Report Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

Print article Print article
© Marketwire 2013
2013-03-11 13:50:55 -

NEW YORK, NY -- (Marketwire) -- 03/11/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares surged 17.45 percent on volume of 7.18 million shares traded Friday to close at $12.32 a share. Cantor Fitzgerald has recently upgraded its price target on Celldex Therapeutics from $13 to $16 and has a "buy" rating on the company.

Find out more about Celldex Therapeutics including full access to the free equity report at: :

Quicksilver Resources Inc. (NYSE: KWK) shares rallied 14.59 percent on volume of 5.73 million shares traded Friday to close at $2.12 a share. The company reported production for the full year 2012 was 132 Bcfe, or an average of 360 MMcfed. Production for the first quarter of 2013 is expected to be 360 - 365 MMcfe per day.

Find out more about Quicksilver Resources including full access to the free equity report at: :

Skullcandy Inc. (NASDAQ: SKUL) shares plunged 22.47 percent on nearly eight times the average daily volume Friday to close at $5.21 a share. The company expects to post a loss of $ of $0.25 to $0.30 per share in the fiscal first-quarter and experience an approximate 30 percent decline in sales.

Find out more about Skullcandy including full access to the free equity report at: :

Sequenom, Inc. (NASDAQ: SQNM) shares declined 4.0 percent on volume of 9.33 million shares traded Friday to close at $4.31 a share. The company announced that their net loss grew to $32.8 million or $0.29 per share, for the fourth quarter of 2012, compared to a net loss of $22.2 million, or $0.22 per share, a year ago.

Find out more about Sequenom including full access to the free equity report at: :

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information:

Equity News Circuit
Email Contact :

Press Information:

Contact Person:

Disclaimer: (c) 2014 Market Wire. All of the press releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Market Wire's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact